ARIE BELLDEGRUN, M.D.; DAVID E. WEBB, M.D.; HOWARD A. AUSTIN III, M.D.; SETH M. STEINBERG, Ph.D.; DONALD E. WHITE; WILLIAM M. LINEHAN, M.D.; STEVEN A. ROSENBERG, M.D., Ph.D.
Adoptive transfer of autologous lymphokine-activated killer cells in conjunction with recombinant interleukin-2 in patients with advanced cancer has produced significant regression of metastatic disease in selected patients. We analyzed the effects of interleukin-2 regimens on renal function in 99 consecutive patients. Interleukin-2 therapy with or without lymphokine-activated killer cells was associated with varying degrees of hypotension, fluid retention, azotemia, oliguria, and low fractional sodium excretion. After the patients completed the interleukin-2 regimens, their renal function improved promptly. Renal function values returned to baseline levels within 7 days in 62% of patients, within 14 days in 84%, and within 30 days in 95%. Pretherapy serum creatinine values above 1.4 mg/dL predicted the severity of azotemia and prolonged duration of renal functional recovery. Interleukin-2 therapeutic regimens induce prerenal azotemia. Careful selection of patients and early detection of adverse physiologic changes may alleviate the side effects of interleukin-2 therapy.
BELLDEGRUN A, WEBB DE, AUSTIN HA, STEINBERG SM, WHITE DE, LINEHAN WM, et al. Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer. Ann Intern Med. ;106:817–822. doi: 10.7326/0003-4819-106-6-817
Download citation file:
Published: Ann Intern Med. 1987;106(6):817-822.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use